Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

Shadi Alkhayyat; Hayder M. Al‐kuraishy; Ali I. Al‐Gareeb; Maisra M. El‐Bouseary; Amal M. AboKamer; Gaber El‐Saber Batiha; Jesus Simal Gandara

doi:10.1007/s00011-022-01615-w

Related publications

Article2020

Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications

Wei‐Yi Ong, Mei‐Lin Go, De Yun Wang, Irwin K. Cheah, Barry Halliwell

Molecular Neurobiology

Article2021

Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?

Alexander Hooftman, Luke O'neill

Current Research in Pharmacology and Drug Discovery

Preprint2022

Home-use Photobiomodulation Device Treatment Outcomes for COVID-19

Lew Lim, Nazanin Hosseinkhah, Mark Van Buskirk, Andrea Berk, Genane Loheswaran, Zara Abbaspour, Mahta Karimpoor, Alison Smith, Yoke N. Au, Kai F Ho, Abhiram Pushparaj, Michael Zahavi, Alexander White, Jonathan Rubine, Brian Zidel, Christopher Henderson, Russell Gene Clayton, David Roy Tingley, David J. Miller, Mahroo Karimpoor, Michael R Hamblin

Article1993

Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part I).

JEAN PAUL HERRMAN, Walter Hermans, J. Cornelis de Vos, Patrick W. Serruys

PubMed

Article2020

Key words to be adopted for COVID-19 research

Aldo Maggioni, Claudio Rapezzi, Luigi Tavazzi, Roberto Ferrari